Minerva Neurosciences
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1500 District Ave, Burlington, Massachus...Phone Number
(617) 600-7373Website
www.minervaneurosciences.comRevenue
-Stock Symbol
NERVIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
2
1
1
1
About Minerva Neurosciences
Minerva Neurosciences is a pharmaceutical company founded in 2007 that focuses on developing innovative treatments for neurological and psychiatric disorders. The company's portfolio includes compounds in various stages of development targeting conditions such as schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Minerva Neurosciences is publicly traded on the NASDAQ Global Market and operates multiple locations across North America, advancing its mission to address significant unmet medical needs in neuroscience.Explore more
Minerva Neurosciences Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Minerva Neurosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Minerva Neurosciences
Earning: See what the market has to say on Minerva Neurosciences recently announced quarterly report
Product Launch: Get notified when Minerva Neurosciences launches new products
Click to see if Minerva Neurosciences had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if Minerva Neurosciences has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Minerva Neurosciences has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Minerva Neurosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Minerva Neurosciences is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Minerva Neurosciences
Compare insights from companies similar to Minerva Neurosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Minerva Neurosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Minerva Neurosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Minerva Neurosciences.
Minerva Neurosciences financials insights
Gather financial insights about Minerva Neurosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Stock Offering
$29.9M
2015
Debt
$15M
Share Placement
$31M
2016
Stock Offering
$53.7M
2017
Stock Offering
$44.6M
2025
Stock/Share Issuance
$200M
Minerva Neurosciences Tech Stack
A closer look at the technologies used by Minerva Neurosciences
See more technologies
Most Recent Scoops
Project
Minerva Neurosciences has reported relapse rates of 9% in one prior study and 13 to 14% in another for roluperidone, compared to 20 to 35% observed in randomized withdrawal studies with antipsychotics.
Project
Minerva Neurosciences has observed that placebo response varied between its prior roluperidone studies, with a 1.6-point reduction in the first study and a 3.5-point reduction in the second, attributing the higher placebo response in the second study to a larger study size, more clinical sites, increased patient interaction, and the drug's favorable tolerability profile making blinding more difficult.
Project
Minerva Neurosciences has reported that roluperidone achieved a 6 to 7-point improvement on the PSP functional scale in prior studies, exceeding the 6-point clinically meaningful threshold established in the literature, with responder and anchor analyses anchored to CGI-S confirming highly significant improvement versus placebo for the 64 mg dose in both studies.
Project
Minerva Neurosciences has announced that the Phase IB readout, evaluating relapse of positive symptoms versus antipsychotics, is expected in the second half of 2028.
Pharmaceuticals
Project
Clinical Operations
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Minerva Neurosciences
Sign Up For FreeTo access detailed company insights
Minerva Neurosciences is a pharmaceutical company founded in 2007 that focuses on developing innovative treatments for neurological and psychiatric disorders. The company's portfolio includes compounds in various stages of development targeting conditions such as schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Minerva N... Read More
